Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychedelic Microdosing: A Subreddit Analysis
Toby Lea, Nicole Amada, Henrik Jungaberle
Journal of Psychoactive Drugs (2019) Vol. 52, Iss. 2, pp. 101-112
Closed Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
Joseph Peill, Katie Trinci, Hannes Kettner, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 31-45
Open Access | Times Cited: 102
The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field
Vince Polito, Paul Liknaitzky
Neuroscience & Biobehavioral Reviews (2022) Vol. 139, pp. 104706-104706
Open Access | Times Cited: 69
Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
Nadia R. P. W. Hutten, Natasha L. Mason, Patrick C. Dolder, et al.
European Neuropsychopharmacology (2020) Vol. 41, pp. 81-91
Open Access | Times Cited: 94
Microdosing psychedelics: Motivations, subjective effects and harm reduction
Toby Lea, Nicole Amada, Henrik Jungaberle, et al.
International Journal of Drug Policy (2019) Vol. 75, pp. 102600-102600
Closed Access | Times Cited: 85
Acute Mood-Elevating Properties of Microdosed Lysergic Acid Diethylamide in Healthy Volunteers: A Home-Administered Randomized Controlled Trial
Robin J. Murphy, Rachael L. Sumner, William J. Evans, et al.
Biological Psychiatry (2023) Vol. 94, Iss. 6, pp. 511-521
Open Access | Times Cited: 28
The costs and benefits of psychedelics on cognition and mood
Ceyda Sayalı, Frederick S. Barrett
Neuron (2023) Vol. 111, Iss. 5, pp. 614-630
Open Access | Times Cited: 24
Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research
Roger S. McIntyre, Angela T.H. Kwan, Rodrigo B. Mansur, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 21-32
Closed Access | Times Cited: 1
The therapeutic potential of microdosing psychedelics in depression
Kim P. C. Kuypers
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 58
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
Marcus W. Meinhardt, Cansu Güngör, Ivan Skorodumov, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 8, pp. 1316-1322
Open Access | Times Cited: 53
Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders
Toby Lea, Nicole Amada, Henrik Jungaberle, et al.
Psychopharmacology (2020) Vol. 237, Iss. 5, pp. 1521-1532
Closed Access | Times Cited: 51
Psychedelics as a Treatment for Alzheimer’s Disease Dementia
Simon Vann Jones, Allison O’Kelly
Frontiers in Synaptic Neuroscience (2020) Vol. 12
Open Access | Times Cited: 51
Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers
Joseph M. Rootman, Pamela Kryskow, Kalin Harvey, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 51
Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience
David W. Lawrence, Robin Carhart‐Harris, Roland R. Griffiths, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 36
LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility
Isabel Wießner, Rodolfo Olivieri, Marcelo Falchi, et al.
European Neuropsychopharmacology (2022) Vol. 58, pp. 7-19
Closed Access | Times Cited: 32
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 32
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Michael Tagen, Daniel Mantuani, Liron van Heerden, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 9, pp. 876-890
Closed Access | Times Cited: 20
Nootropic effects of LSD: Behavioral, molecular and computational evidence
Isis M. Ornelas, Felipe A. Cini, Isabel Wießner, et al.
Experimental Neurology (2022) Vol. 356, pp. 114148-114148
Open Access | Times Cited: 23
Psilocybin’s effects on cognition and creativity: A scoping review
Justin N Bonnieux, Baeleigh VanderZwaag, Zahra Premji, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 635-648
Open Access | Times Cited: 15
Investigating Substance Use via Reddit: Systematic Scoping Review
Yu Chi, Huai-yu Chen
Journal of Medical Internet Research (2023) Vol. 25, pp. e48905-e48905
Open Access | Times Cited: 15
State Cannabis and Psychedelic Legislation and Microdosing Interest in the US
Kevin H. Yang, Nora Satybaldiyeva, Matthew R. Allen, et al.
JAMA Health Forum (2024) Vol. 5, Iss. 6, pp. e241653-e241653
Open Access | Times Cited: 4
Self‐reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities
Noa Krawczyk, Megan Miller, Emma Yuanqi Gu, et al.
Addiction (2025)
Closed Access
Side Effects of Microdosing Lysergic Acid Diethylamide and Psilocybin: A Systematic Review of Potential Physiological and Psychiatric Outcomes
Stefan Modzelewski, Anna Stankiewicz, Napoleon Waszkiewicz, et al.
Neuropharmacology (2025), pp. 110402-110402
Closed Access
Societal perspectives on psychedelics use in clinical context: Development of Concerns and Openness towards Psychedelic Scale (COPS)
Paweł Holas, Justyna Kamińska, Marcin Zajenkowski
Dialogues in Clinical Neuroscience (2025) Vol. 27, Iss. 1, pp. 11-21
Open Access
Do undergraduates’ views of psychedelics relate to the context for psychedelic use?
Dan Petrovitch, Jason Van Allen, Sean M. Mitchell, et al.
Drug Science Policy and Law (2025) Vol. 11
Closed Access
Motives for the use of serotonergic psychedelics: A systematic review
Lukas A. Basedow, Sören Kuitunen‐Paul
Drug and Alcohol Review (2022) Vol. 41, Iss. 6, pp. 1391-1403
Closed Access | Times Cited: 19
Page 1 - Next Page

Scroll to top